|Source||Humanized (from mouse)|
|Drug class||TNF inhibitor|
|Main uses||Crohn's disease, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis|
|Side effects||Infections, low white blood cells, nausea, headache, numbness, high blood pressure, liver inflammation, rash, pain at the site of injection|
|US NLM||Certolizumab pegol|
|Elimination half-life||about 11 days|
|Excretion||Kidney (PEG only)|
|Chemical and physical data|
|Molar mass||47749.46 g·mol−1|
Certolizumab pegol, sold under the brand name Cimzia, is a medication used to treat Crohn's disease, rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, and ankylosing spondylitis. It is given by injection under the skin.
Common side effects include infections such as abscesses, low white blood cells, nausea, headache, numbness, high blood pressure, liver inflammation, rash, and pain at the site of injection. Other side effects may include cancer, heart failure, and angioedema. It is a fragment of a monoclonal antibody that binds to tumor necrosis factor alpha (TNF-α).
Certolizumab pegol was approved for medical use in the United States in 2008 and Europe in 2009. It is on the World Health Organization's List of Essential Medicines as an alternative to adalimumab. In the United Kingdom 400 mg costs the NHS about £715 as of 2021. This amount in the United States costs about 4,700 USD.
Significant side effects occur in 2% of people.
Method of action
- Crohn's disease
- Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol versus placebo in moderate to severe active Crohn's disease.
- Axial spondyloarthritis
- In 2013, a phase 3 double blind randomized placebo-controlled study found significantly positive results in patient self-reported questionnaires, with rapid improvement of function and pain reduction, in patients with axial spondyloarthritis.
- "Cimzia- certolizumab pegol kit Cimzia- certolizumab pegol injection, solution". DailyMed. 24 April 2020. Archived from the original on 19 July 2020. Retrieved 18 July 2020.
- "Cimzia". Archived from the original on 30 December 2021. Retrieved 3 January 2022.
- "Certolizumab Monograph for Professionals". Drugs.com. Archived from the original on 22 January 2021. Retrieved 3 January 2022. Cite error: Invalid
<ref>tag; name "AHFS2022" defined multiple times with different content
- World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1159. ISBN 978-0857114105.
- "Cimzia Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 3 January 2022.
- "Drug Approval Package: Cimzia (Certolizumab Pegol) NDA #125160". U.S. Food and Drug Administration (FDA). 24 December 1999. Archived from the original on 19 July 2020. Retrieved 18 July 2020.
- UCB press release - Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease Archived 2012-02-18 at the Wayback Machine. Retrieved April 22, 2008.
- Waknine, Yael (May 1, 2008). "FDA Approvals: Patanase, Actonel, Cimzia". Medscape. Archived from the original on 2019-12-08. Retrieved 2008-05-01.
- Ruiz Garcia, V; Jobanputra, P; Burls, A; Vela Casasempere, P; Bort-Marti, S; Bernal, JA (Sep 8, 2017). "Certolizumab pegol (CDP870) for rheumatoid arthritis in adults" (PDF). The Cochrane Database of Systematic Reviews. 2017 (9): CD007649. doi:10.1002/14651858.CD007649.pub4. PMC 6483724. PMID 28884785. Archived (PDF) from the original on November 1, 2021. Retrieved October 5, 2021.
- Lee JU, Shin W, Son JY, Yoo KY, Heo YS (January 2017). "Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases". Int J Mol Sci. 18 (1): 228. doi:10.3390/ijms18010228. PMC 5297857. PMID 28124979.
- Schreiber S. et al., Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase 3 study (precise), Gut, 2005, 54, suppl7, A82
- Sandborn WJ, Feagan BG, Stoinov S, et al. (July 2007). "Certolizumab pegol for the treatment of Crohn's disease". N. Engl. J. Med. 357 (3): 228–38. doi:10.1056/NEJMoa067594. PMID 17634458.
- Goel, Niti; Sue Stephens (2010). "Certolizumab pegol". mAbs. 2 (2): 137–147. doi:10.4161/mabs.2.2.11271. PMC 2840232. PMID 20190560. Archived from the original on 2012-03-23. Retrieved 2021-10-05.
- Sandborn et al., Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled Phase 3 study (PRECiSE 1), Gastroenterology, 2006, 130, A107
- "New Analysis Shows Cimzia (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease" (Press release). UCB. October 23, 2006. Archived from the original on 2020-03-29. Retrieved 2009-11-15.
- Sieper J, Tubergen A, Coteur G, Woltering F, Landewe R (May 2013). "PMS50 – Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study". Value in Health. 16 (3): A227. doi:10.1016/j.jval.2013.03.1150.